Patients with focal segmental glomerulosclerosis show partial remission with sparsentan

In clinical trials, sparsentan proved more effective in reducing proteinuria vs. irbesartan in adults with focal segmental glomerulosclerosis, but there was no major change in GFR among patients on the two drugs, a study found.
In the phase 3 Duplex trial of sparsentan, a dual endothelin–angiotensin receptor antagonist, researchers randomly enrolled 371 patients, aged 8 to 75 years, with focal segmental glomerulosclerosis (FSGS) and no known secondary causes. In the study, 184 received sparsentan and 187 received irbesartan for 108 weeks. The primary endpoint was eGFR slope at final

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart